These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22539226)

  • 1. Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
    Tweats D; Bourdin Trunz B; Torreele E
    Mutagenesis; 2012 Sep; 27(5):523-32. PubMed ID: 22539226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
    Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
    Trunz BB; Jędrysiak R; Tweats D; Brun R; Kaiser M; Suwiński J; Torreele E
    Eur J Med Chem; 2011 May; 46(5):1524-35. PubMed ID: 21353728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
    Kaiser M; Bray MA; Cal M; Bourdin Trunz B; Torreele E; Brun R
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5602-8. PubMed ID: 21911566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel drugs for human African trypanosomiasis.
    Brun R; Don R; Jacobs RT; Wang MZ; Barrett MP
    Future Microbiol; 2011 Jun; 6(6):677-91. PubMed ID: 21707314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fexinidazole: First Global Approval.
    Deeks ED
    Drugs; 2019 Feb; 79(2):215-220. PubMed ID: 30635838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
    Tarral A; Blesson S; Mordt OV; Torreele E; Sassella D; Bray MA; Hovsepian L; Evène E; Gualano V; Felices M; Strub-Wourgaft N
    Clin Pharmacokinet; 2014 Jun; 53(6):565-80. PubMed ID: 24535888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.
    Watson JA; Strub-Wourgraft N; Tarral A; Ribeiro I; Tarning J; White NJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro genotoxicity of para-phenylenediamine and its N-monoacetyl or N,N'-diacetyl metabolites.
    Garrigue JL; Ballantyne M; Kumaravel T; Lloyd M; Nohynek GJ; Kirkland D; Toutain H
    Mutat Res; 2006 Sep; 608(1):58-71. PubMed ID: 16807077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.
    Filali-Ansary A; Augé C; Abgrall A; Souchaud M; Pellissier F; Mordt OV; Blesson S; Sanderink GJ
    Bioanalysis; 2016 Oct; 8(19):2045-63. PubMed ID: 27611920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
    Wyllie S; Patterson S; Stojanovski L; Simeons FR; Norval S; Kime R; Read KD; Fairlamb AH
    Sci Transl Med; 2012 Feb; 4(119):119re1. PubMed ID: 22301556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests.
    Schwen R; Jackson R; Proudlock R
    Food Chem Toxicol; 2010 Dec; 48(12):3481-5. PubMed ID: 20875837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo chromosomal aberrations induced by megazol.
    Nesslany F; Brugier S; Mouriès MA; Le Curieux F; Marzin D
    Mutat Res; 2004 Jun; 560(2):147-58. PubMed ID: 15157652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.
    Bernhard S; Kaiser M; Burri C; Mäser P
    Diseases; 2022 Oct; 10(4):. PubMed ID: 36278589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutagenic and clastogenic activity of the chloro-nitroimidazole radiosensitizer P40 in vitro and in vivo.
    Konopacka M; Wideł M; Grzybowska E; Suwiński J
    Pol J Pharmacol Pharm; 1992; 44(3):299-306. PubMed ID: 1470567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotoxic effects of the antileishmanial drug Glucantime.
    Lima MI; Arruda VO; Alves EV; de Azevedo AP; Monteiro SG; Pereira SR
    Arch Toxicol; 2010 Mar; 84(3):227-32. PubMed ID: 19911167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fexinidazole for the treatment of human African trypanosomiasis.
    Fairlamb AH
    Drugs Today (Barc); 2019 Nov; 55(11):705-712. PubMed ID: 31840685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy against human African trypanosomiasis: is there a road to success?
    Burri C
    Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid is not metabolized by Salmonella or human nitroreductases: A possible mechanism for the lack of mutagenicity.
    Hanaki E; Hayashi M; Matsumoto M
    Regul Toxicol Pharmacol; 2017 Mar; 84():1-8. PubMed ID: 27988333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
    Kirkland D; Aardema M; Henderson L; Müller L
    Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.